Social Impact Report 2023 - 2024
Financial report
We’re ready to support more NHS referrals from outside London and offer self-referrals for those seeking our expertise
Funding what matters
To create the lasting impact we’re aiming for, financial stability is a must. In 2023/24, we posted a pre-tax surplus of £9,219 while also making strategic investments in our team’s education, regular team meetups, and a dedicated space for our Patient Group – each vital to our mission.
A sustainable future means getting smarter: streamlining operations and embracing digital technology to boost productivity and cut costs. The graph below makes it clear – we need to boost revenue to meet rising costs and keep delivering for our community.
The future looks bright
Accelerate is known for delivering high-quality care, excellent education, and exceptional customer support across all our services. This strong reputation will drive our 2024/25 initiatives, particularly in the Academy, as we expand access to specialist care. We’re ready to support more NHS referrals from outside London and offer self-referrals for those seeking our expertise. Education that leads to real change remains a key focus of our mission and impact.
Closing the gaps in care
Wounds cost the NHS around £8 billion a year, but lymphoedema is the silent epidemic draining the health system too. If you mapped lymphoedema services across the UK, it would look like Swiss cheese – full of gaps where people are left without support to manage this long-term condition. Too many are slipping through the cracks.
We’re stepping up to change that by opening our doors to patients beyond our region. Whether through GP referrals or self-referral for those who can afford it, we’re here to help those struggling with swollen limbs and repeated infections. And we’re not stopping there – we’ll continue supporting people with non-healing wounds, working with local teams to improve outcomes through education and hands-on practice.
We’ve seen a tsunami of referrals this year, with a 39% year-on-year increase. Despite this surge and no additional funding, we have continued to meet the extra demand and achieve great outcomes for our patients.
Accelerate